| Sector |
Drug Discovery
|
|---|---|
| Region |
London, UK
|
| Stage |
Growth
|
| Fund | Life Sciences EIS |
| Target Raise |
£1m
|
Elasmogen’s soloMER™ is an anti-inflammatory drug designed to be delivered to specific sites within the human body.
The Investment Opportunity
Elasmogen is a biological drug discovery company which aims to serve the cancer therapeutics market. The Company has developed an IP-protected method of exploiting the power of biologics to deliver drugs to very small specific sites in the human body that currently are difficult to treat.
In this particular case, the Company’s ‘soloMER’ products are site-specific drug delivery proteins derived from shark antibodies. Shark antibodies are incredibly small (considerably smaller than a human antibody) and are highly stable proteins, making them ideal for both site-specific delivery in very small areas and the penetration of solid cancerous tumours.
Elasmogen initially developed its domains around the treatment of Uveitis, which concerns the inflammation of the coloured section of the eye and can lead to eye pain and changes in vision, but can be used for treating numerous conditions. This has led the Company to further develop their methodology for oncology and has continued development with the core products now targeting differentiated auto-immune diseases. This has included “NDure”, a soloMER product that has been developed to extend the active effect of drugs in the gut, making treatment more controllable and sustained. The Company has also received grant funding to explore the use of their domain for the treatment of Coronaviruses.
Milestones to Date
| 2016 | Deepbridge initially invested £150k via the Deepbridge Life Sciences SEIS. |
|---|---|
| 2017 | CEO, Dr Caroline Barelle, named “Rising Stars: Extraordinary Talent 2017” at Scotland’s Life Sciences Annual Awards. |
| 2018 | Elasmogen winner of BioFIT 2018 Start-up Slams. |
| 2109 | CEO, Dr Caroline Barelle, featured in BioBeats “50 Movers and Shakers in BioBusiness 2019”. |
| 2020 | Awarded two grants worth £374k for Covid-19 and oncology programmes. |
Risks and Important Information
This page is a financial promotion for the purposes of Section 21 of the Financial Services and Markets Act 2000. The content of the page has been approved by Deepbridge Capital LLP. The Company may not gain the commercial traction that is forecast, it could experience development problems and may not be able to achieve its objectives. Please note that these risks are by no means exhaustive and there may be other risks which could have a material adverse impact on the Company’s financial performance. The content should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors could lose the total value of their investment. Investments in small unquoted companies carry a high- level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Tax treatment depends on the individual circumstances of each investor and may be subject to change in future. The availability of tax reliefs depends on the Company invested in maintaining its qualifying status. Deepbridge does not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.
About Tech South West:
Celebrating and showcasing the South West's fastest-growing sector. Tech South West has hundreds of members across the region; join today to become a part of the South West tech community.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.